TaiMed Biologics’ Trogarzo (ibalizumab-uiyk) Receives Approval for Multidrug Resistant (MDR)-HIV

 TaiMed Biologics’ Trogarzo (ibalizumab-uiyk) Receives Approval for Multidrug Resistant (MDR)-HIV

TaiMed Biologics’ Trogarzo (ibalizumab-uiyk) Receives Approval for Multidrug Resistant (MDR)-HIV

Shots:

  • The approval is based on clinical study results assessing Trogarzo (ibalizumab, IV) in 40 patients with MDR-HIV
  • The study resulted in depletion of HIV-RNA level in blood in 43% patients after 24 weeks when given with other antiretroviral drugs
  • Trogarvo (ibalizumab, IV) is an antiretroviral drug used in treatment of MDR-HIV and received FDA’s FT, PR, OD and breakthrough therapy in 2003, 2017, 2014 & 2015 respectively.

Click here to read full press release/ article | Ref: FDA | Image: Bioworld

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post